Transplant-related mortality and morbidity (both short and long term) have limited the effectiveness of SCT in children with both malignant and nonmalignant diseases. Reducedintensity preparative regimens permit engraftment of allogeneic cells without many of the toxicities associated with standard TBI-and non-TBI-based conditioning. We review the concepts that underlie reduced-intensity transplantation (RIT) and highlight the experience of the technique in children. Although acute organ damage may be reduced after these transplants, the overall incidence of severe infections and of GvHD may be similar to that seen after standard-intensity transplantation. The relatively small numbers of children who have received RIT and the newness of the technique preclude long-term follow-up with which to monitor the incidence of associated long-term side effects and disease-free survival. Future refinements in RIT and appropriate patient selection for these procedures will hopefully extend its utility in the future.
Allogeneic hematopoietic SCT (HSCT) using conventional standard myeloablative conditioning regimens has been well established as a curative treatment modality. Associated with extensive short-and long-term morbidity and a high mortality rate, such stem cell transplants were denied to many high-risk patients with nonmalignant diseases or comorbidities who could have theoretically benefited from the procedure.
Several lines of evidence from the world of pediatric SCT suggested that the aggressive pretransplant conditioning administered to stem cell transplant recipients could be replaced by milder and less toxic regimens.
Reduced-intensity transplants have been used for the treatment of patients with Fanconi's anemia who tolerated myeloablative conditioning poorly due to excessive chromosomal breakage after such treatment. These patients suffering from BM failure experience reliable engraftment following low-dose CY and thoracoabdominal irradiation. Patients with idiopathic severe aplastic anemia experience full-donor engraftment following purely immunosuppressive conditioning (CY with or without antithymocyte globulin). Although usually limited to lymphoid cells, cases of full-donor hematopoietic engraftment have been reported in babies with SCID transplanted without conditioning.
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The ability of engrafting cells to eradicate residual leukemia has long been inferred from increased leukemiafree survival rates among patients who received reduced GvHD prophylaxis and from the effect of donor lymphocyte infusions in patients with recurrent leukemia following SCT, where an immune-mediated GVL effect is most evident.
Minimum requirements for transplant conditioning include sufficient immune suppression to promote shortterm engraftment of hematopoietic precursors, while the donor lymphocytes contained within the graft promote donor chimerism and antitumor effect to maintain posttransplant remission.
The common theme in reduced-intensity regimens is that the preparative therapy spares primitive hematopoietic precursors of host origin, such that autologous hematopoietic recovery would be expected within 1 month in the absence of donor stem cell infusion. Most patients treated with these protocols have been selected for their inability to tolerate fully myeloablative conditioning due to various comorbidities. Different regimens vary in their intensity, with some regimens causing little or no myelosuppression, and others inducing a greater degree of this complication.
In patients with nonmalignant diseases, reduced-intensity transplantation (RIT) is used to replace defective host hematopoiesis with normal donor cells, or to provide a missing factor or enzyme in the host.
Hematopoiesis following RIT changes gradually from host to donor origin. Full-donor chimerism is not a prerequisite for success of HCT, particularly in patients with nonmalignant disease, and a state of stable mixed chimerism may reduce the rate of severe GvHD in these patients.
In all likelihood, donor cells gain the upper hand following RIT using 'veto' capabilities. 3 Veto cells, which include both certain T-cell subsets and CD34 þ cells, eliminate host cells capable of mounting a host-vs-graft reaction, tilting the battle for immune predominance in favor of grafted cells. 4, 5 Reduced-intensity transplantation should theoretically provide a solution to overcome the barriers and risks of conventional transplants. RIT can often be performed on an outpatient basis, might pose little threat to the patient's growth potential or fertility, and should result in fewer serious side effects on specific organs.
We last reviewed pediatric RIT 4 years ago, and we summarize recent advances in this mini review.
Results
Unfortunately, the toxicity of RIT regimens is somewhat higher than had been originally expected. Among the 21 children transplanted by Del Toro et al., using RIT conditioning (14 unrelated cord blood and 7 matched family donors), grade 3 or 4 nonhematologic toxicity was considerable, and included hemorrhagic cystitis, hepatotoxicity, pancreatitis, severe nausea and vomiting, and 43 severe infections (including bacteremia, fungal, mycobacterial and severe viral infections). TRM analysis needs to be redefined to include events after day 100. Incidence over 25% has been reported in many series, a number that needs to be understood in the context of the high-risk population that is usually selected for this type of procedure. Although patient costs of RIT are probably lower than those associated with myeloablative transplant, overall costs may be surprisingly high 6 due to delayed onset of severe infections including EBV reactivation. 7 As compared with standard conditioning, the incidence and severity of acute GvHD following RIT is lower in most published series; however, the incidence and severity of chronic GvHD was reported to be higher and tended to occur later. These observations may be explained by factors such as the conditioning regimens and reduced level of cytokine storm, source of stem cells and the use of donor lymphocyte infusion (DLI). 8 The long-term toxicities of RIT are, of course, as yet unknown. It would be expected that most RIT regimens would have minimal effects on reproductive or endocrine function, but longer follow-up will be needed before this issue can be addressed. For example, we do not know the threshold dose of BU for critical germ cell loss in children and adolescents.
Myeloid and T-cell engraftment following RIT is probably faster in patients who have been exposed to chemotherapy before the transplant procedure as opposed to chemotherapy-naive patients, 9 although some patients with nonmalignant diseases also engraft well after RIT regimens. 10 Fludarabine is used in most RIT regimens, although pentostatin has been used in some protocols with good results. 11 The addition of fludarabine to an immunosuppressive regimen of low-dose TBI coupled with posttransplant CsA and mycophenolate mofetil increased engraftment rates dramatically. 12 The most widely used RIT protocols with dose variations include:
The Seattle protocol: fludarabine, low-dose TBI and post-transplant CsA and mycophenolate mofetil. 13 The Jerusalem protocol: fudarabine, fresenius antithymocyte globulin and 'minimal' cytotoxic therapy (either BU 8 mg/kg or CY 120 mg/kg). 14 The MD Anderson protocol (and its variations): fludarabine and Ara-C, melphalan, CY or an anthracycline. 15 Patients with indolent and some nonmalignant diseases might fare well with milder conditioning therapy to permit donor engraftment and eventual elaboration of the graftvs-malignancy reaction without the need for cytotoxic bridging therapy. Patients with primary refractory hematologic disease, hemoglobinopathies, myelodysplastic syndrome (MDS), hemophagocytic lymphohistiocytosis or severe aplastic anemia may require more intense nonmyeloablative conditioning and immunosuppression to prevent graft rejection. Because transplant-related morbidity after RIT is low, in these patients with graft failure, a second transplant with a myeloablative regimen may be feasible.
Most reports of RIT involve the use of HLA-matched sibling donors, while unrelated HLA-matched donors have been used in some series. Although megadose (41 Â 10 6 /kg CD34 þ cells/kg) stem cell infusions have been reported, 16 more conventional doses of stem cells from either the peripheral blood or marrow are sufficient for both engraftment and GVL effects under most circumstances. 9, 13 Interestingly, umbilical cord blood from unrelated donors has been reported as a useful stem cell source for RIT. [17] [18] [19] Published experience with RIT in children is summarized in Table 1 . Del Toro et al. 19 reported a series of 21 patients aged 0.5-21 years with a variety of diseases (including Hodgkin's and non-Hodgkin's lymphoma, leukemia, solid tumors, genetic defects and nonmalignant hematological diseases) who were transplanted from matched family donors or unrelated cord blood units. Most patients received variations of the Jerusalem protocol, while GvHD prophylaxis included both tacrolimus and mycophenolate mofetil. Most patients experienced donor cell engraftment, and survival for good risk patients was excellent. Kletzel et al. 30 reported 84% 1-year survival in nonmalignant diseases and 4/11 long-term remissions in patients with ALL and very high risk features.
Objective responses have been seen in patients suffering from metastatic solid tumors following allogeneic RIT transplantation. 31 The small number of children suffering from solid tumors who have been subjected to RIT precludes conclusions on the efficacy of this modality in pediatric practice.
Studies using RIT regimens for patients with a variety of nonmalignant diseases have included congenital immunodeficiencies, 26, 27 enzyme deficiencies, hematological disorders, [20] [21] [22] [23] [24] [25] 28, 29 hemophagocytic lymphohistiocytosis 32 and osteopetrosis. 33 RIT was associated with increased risk of failure in patients with hemoglobinopathies, resulted in high engraftment rates and was well tolerated by children with congenital immunodeficiencies even in the presence of organ dysfunction. In this later group of patients, RIT may be the preparation of choice in the unrelated donor setting. Horn et al. 28 have observed 89% survival using targeted BU/fludarabine/antithymocyte globulin in children with nonmalignant disease, but there was a high incidence of graft failure in patients undergoing mismatched unrelated donor transplantation and in patients with a history of multiple blood transfusions. For these patients, a regimen with intensified immunosuppression might be more appropriate. Resnick et al. 34 recently reported 100% survival and 80% thalassemia-free survival among 20 children treated with fludarabine, high-dose BU and ATG.
Because trilineage engraftment is a protracted and often incomplete process following RIT (mixed hematopoietic chimerism), evaluation of the percentage of donor or recipient signal in a sample of whole blood may give misleading results. Use of FISH and analysis of shorttandem repeats on leukocyte subfractions obtained by FACS may be used to prospectively evaluate engraftment. Serial evaluation of the extent of chimerism in different cellular subfractions is an indispensable tool for the clinician performing RIT, as it enables the judicious tapering of immunosuppression and the timely application of donor lymphocyte infusions that represent a potential adjuvant of RIT, where immune-mediated tumor cell destruction is the prerequisite for success of the procedure. 35 
Conclusions
Reduced-intensity transplantation is a new technology that promises to revolutionize the way that SCT is performed. Multi-institutional and group-wide prospective studies of RIT are urgently needed so that we can define the optimal regimens and the optimal candidates for this form of transplant. The monetary and staffing costs, short-and long-term side effects and rates of disease control need to be carefully evaluated before RIT can replace conventional stem cell transplant regimens in children with malignant and nonmalignant diseases. It will be a logistic and ethical challenge to design and implement studies in which some patients receive highly toxic conditioning, while others receive treatment on a semi-ambulatory basis. Patient recruitment to such a study might be hampered by parental bias as to the 'safest' form of treatment for their child. Alternatively, uniform use of a limited number of regimens according to disease-and patient-specific criteria coupled with organized data capture would permit case-matched comparison with patients undergoing standard SCT. Prospective multicenter studies that stratify patients for underlying disease, stem cell source and comorbidities are urgently required before evidence-based decisions regarding which RIT regimen is appropriate for a specific patient are possible. 
